SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction
Avula V, Sharma G, Kosiborod M, Vaduganathan M, Neilan T, Lopez T, Dent S, Baldassarre L, Scherrer-Crosbie M, Barac A, Liu J, Deswal A, Khadke S, Yang E, Ky B, Lenihan D, Nohria A, Dani S, Ganatra S. SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction. JACC Heart Failure 2023, 12: 67-78. PMID: 37897456, DOI: 10.1016/j.jchf.2023.08.026.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic AgentsCardiomyopathiesDiabetes Mellitus, Type 2FemaleHeart FailureHumansMaleNeoplasmsRetrospective StudiesSodium-Glucose Transporter 2 InhibitorsConceptsCancer therapy-related cardiac dysfunctionSGLT2 inhibitor useGuideline-directed medical therapyHeart failureInhibitor useSGLT2 inhibitorsMedical therapyCardiac dysfunctionAntineoplastic therapyAtrial fibrillation/flutterType 2 diabetes mellitusAcute HF exacerbationCox proportional HRsAcute kidney injuryRenal replacement therapyRetrospective cohort analysisIschemic heart diseaseRisk of cardiomyopathyAggregate patient dataTriNetX Research NetworkProportional HRsCause hospitalizationCause mortalityHF exacerbationKidney injury